| ARDELYX INC. DL-,0001 |
| USA |
| Gesundheit |
| US0396971071 / A116X0 |
| 41X (Frankfurt) / ARDX (NASDAQ) |
| FRA:41X, ETR:41X, 41X:GR, NASDAQ:ARDX |
| - |
| https://ardelyx.com/ |
|
Ardelyx Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing first-in-class medicines to address unmet medical needs in gastrointestinal and cardio-renal diseases. The company employs an innovative platform that..
>Volltext.. |
| 1066.85 Mio. EUR |
| 1041.1 Mio. EUR |
| 370.89 Mio. EUR |
| -29.53 Mio. EUR |
| -50.35 Mio. EUR |
| -0.21 EUR |
| 180.61 Mio. EUR |
| 27.06 Mio. EUR |
| -31.45 Mio. EUR |
| 2.17 |
| 10.72% |
| -1.12% |
| - |
| - |
| - |
| ARDELYX |
| 07.08.26 |